By switaschek, 27 May, 2020 Postconversion maintenance drug options5 based on CAD LVH HF comorbidities drug risks rate control tx OK to continue antiarrhythmic despite infrequent well tolerated recurrences stop if AF becomes permanent
By switaschek, 27 May, 2020 Postconversion pill-in-pocket prn option: propafenone/flecainide + BB/non-DHP-CCB (diltiazem/verapamil), once proven safe in monitored setting, reasonable to terminate out-pt AF
By switaschek, 27 May, 2020 Pharmacologic cardioversion5 + periprocedural anticoagulation4 + rate-control tx: flecainide, dofetilide, propafenone, IV ibutilide or amiodarone;5 amiodarone preferred if ICVD or structural heart dz, per ESC
By switaschek, 27 May, 2020 DC cardiovert + periprocedural anticoagulation.4 Repeat/serial attempts based on sinus rhythm duration, sx, pt preference4 +/- rate-control tx
By switaschek, 27 May, 2020 Restore sinus rhythm1 via DC cardioversion, antiarrhythmic drug, or RF cath ablation; +/- rate control. Correct underlying causes
By switaschek, 27 May, 2020 Women w/ AF are at increased stroke risk vs men; a study concluded that women
By switaschek, 27 May, 2020 Direct oral anticoagulant (apixaban, dabigatran, rivaroxaban, edoxaban are recommended over warfarin, in absence of mod-severe MS or mech valve)3
By switaschek, 27 May, 2020 Consider anticoagulant options2,3 based on stroke/bleed risks, renal fxn, pt preference